Investors Buy Large Volume of Call Options on Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) was the recipient of some unusual options trading activity on Wednesday. Traders purchased 6,110 call options on the stock. This is an increase of 44% compared to the typical daily volume of 4,234 call options.

More Sarepta Therapeutics News

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Early Phase 1/2 siRNA results point to target knockdown, muscle exposure and tolerability for SRP‑1001 and SRP‑1003 — the primary catalyst behind the rally. Business Wire: Sarepta Announces First Clinical Data
• Positive Sentiment: Multiple outlets and market commentators highlight the clinical readouts as a potential turning point; coverage helped drive heavy volume and momentum into the stock. Yahoo Finance: SRPT Stock Surges
• Positive Sentiment: Some sell‑side moves reflected renewed conviction — Morgan Stanley is reported to have raised its price target (reported widely alongside the trial coverage), which helped fuel the rally. InsiderMonkey: Morgan Stanley PT Hike
• Positive Sentiment: Unusually heavy options and call buying accompanied the move, indicating speculative bullish positioning and short‑term leverage from traders.
• Neutral Sentiment: Several valuation and note‑style writeups are trying to size the opportunity vs. risk — analysts and outlets caution that early Phase 1/2 data need confirmation and that valuation debate will drive near‑term swings. Yahoo/Zacks coverage: Is Further Upside Left?
• Negative Sentiment: Some firms remain skeptical — Citigroup raised a price target modestly but kept a sell rating (cites downside from current levels), and Needham reaffirmed an underperform stance, keeping sell‑side views polarized. Benzinga: Analyst Ratings
• Negative Sentiment: Independent analysts and commentators warn the data are early — some outlets argue it’s too soon to extrapolate durable clinical or commercial success from small Phase 1/2 cohorts. Seeking Alpha: Too Early to Get Excited
• Negative Sentiment: Underlying fundamentals and priorquarter results (recent EPS miss and revenue decline vs. year‑ago) remain a drag on sentiment; this increases the chance of volatility if follow‑up data or guidance disappoints.

Sarepta Therapeutics Price Performance

Shares of NASDAQ:SRPT opened at $21.68 on Friday. The company has a quick ratio of 1.48, a current ratio of 2.32 and a debt-to-equity ratio of 0.73. Sarepta Therapeutics has a fifty-two week low of $10.41 and a fifty-two week high of $73.95. The firm has a 50-day simple moving average of $18.71 and a 200 day simple moving average of $19.97. The company has a market cap of $2.28 billion, a PE ratio of -2.57, a P/E/G ratio of 0.37 and a beta of 0.42.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($2.71). Sarepta Therapeutics had a negative return on equity of 50.74% and a negative net margin of 38.34%.The business had revenue of $442.93 million during the quarter, compared to the consensus estimate of $390.95 million. During the same period in the prior year, the business earned $1.90 EPS. The business’s revenue was down 32.7% on a year-over-year basis. On average, sell-side analysts anticipate that Sarepta Therapeutics will post 2.67 EPS for the current year.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Stephen Mayo sold 7,239 shares of the stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $17.02, for a total transaction of $123,207.78. Following the transaction, the director directly owned 1,765 shares in the company, valued at $30,040.30. This represents a 80.40% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 7.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

Several large investors have recently made changes to their positions in the company. Rockefeller Capital Management L.P. raised its holdings in shares of Sarepta Therapeutics by 98.3% during the fourth quarter. Rockefeller Capital Management L.P. now owns 4,104 shares of the biotechnology company’s stock valued at $88,000 after buying an additional 2,034 shares during the last quarter. Mercer Global Advisors Inc. ADV grew its holdings in Sarepta Therapeutics by 340.7% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 95,752 shares of the biotechnology company’s stock worth $2,061,000 after buying an additional 74,027 shares in the last quarter. EP Wealth Advisors LLC acquired a new stake in Sarepta Therapeutics in the 4th quarter valued at approximately $213,000. Mackenzie Financial Corp increased its position in Sarepta Therapeutics by 17.1% in the 4th quarter. Mackenzie Financial Corp now owns 58,042 shares of the biotechnology company’s stock valued at $1,245,000 after acquiring an additional 8,494 shares during the period. Finally, Virtus Investment Advisers LLC raised its stake in Sarepta Therapeutics by 166.5% during the 4th quarter. Virtus Investment Advisers LLC now owns 31,741 shares of the biotechnology company’s stock valued at $683,000 after acquiring an additional 19,830 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Jefferies Financial Group reissued a “buy” rating and issued a $30.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, March 3rd. Barclays assumed coverage on Sarepta Therapeutics in a research note on Wednesday, January 28th. They set an “equal weight” rating and a $20.00 price objective on the stock. Royal Bank Of Canada increased their target price on Sarepta Therapeutics from $16.00 to $18.00 and gave the stock a “sector perform” rating in a report on Thursday, January 8th. Finally, Needham & Company LLC reiterated an “underperform” rating on shares of Sarepta Therapeutics in a research report on Thursday. Nine analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and six have given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $32.30.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.